Floatz logo

Immunoglobulin G1 [De-236-Glycine,267-Glutamic Acid,De-C-Terminal Lysine], Anti-(Human Tumor Necrosis Factor Receptor Tnfrsf9) (Human-Mus Musculus Monoclonal Lvgn6051 ?1-Chain), Disulfide With Human-Mus Musculus Monoclonal Lvgn6051 ?-Chain, Dimer

Hepatocellular Carcinoma

Explore 499 assets in Hepatocellular Carcinoma →
Floatz Rating
CC43/100
Confidence
Indicative
v0.2
Sponsor
M.D. Anderson Cancer Center
Modality
monoclonal_antibody
Development Phase
Phase 1
Status
Active
Evidence ledger · v0.2

Clinical Evidence

Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
28Indicative
Detailed axis rationale is planned and will be published soon.
TrialPhaseStatusNPrimary endpointReadout
NCT05075993CT.gov
Study of LVGN3616 and LVGN6051±LVGN7409 in Combination With Nab-Paclitaxel or Bevacizumab and Cyclophosphamide in Metastatic Solid Tumors
—Active Not Recruiting———

Competitive Position

Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.

Same indication · Hepatocellular Carcinoma

AssetSponsorPhaseRating
Immunoglobulin G1 [De-236-Glycine,267-Glutamic Acid,De-C-Terminal Lysine], Anti-(Human Tumor Necrosis Factor Receptor Tnfrsf9) (Human-Mus Musculus Monoclonal Lvgn6051 ?1-Chain), Disulfide With Human-Mus Musculus Monoclonal Lvgn6051 ?-Chain, Dimer (this asset)M.D. Anderson Cancer CenterP1CC · 43
AdefovirBukwang PharmaceuticalP4BBB
Huaier GranuleTongji HospitalP4BBB
FluorouracilumLi QiangP4BBB
OxaliplatinLi QiangP4BBB
TheprubicinRWTH Aachen UniversityP4BB
AdriamycinVA Office of Research and DevelopmentP4BB
nrt6003Second Affiliated Hospital of Guangzhou Medical UniversityP3BB
EpirubicinFudan UniversityP4BB

+42 more in the Hepatocellular Carcinoma cohort

Other indications for Immunoglobulin G1 [De-236-Glycine,267-Glutamic Acid,De-C-Terminal Lysine], Anti-(Human Tumor Necrosis Factor Receptor Tnfrsf9) (Human-Mus Musculus Monoclonal Lvgn6051 ?1-Chain), Disulfide With Human-Mus Musculus Monoclonal Lvgn6051 ?-Chain, Dimer

IndicationSponsorPhaseRating
Esophageal Cancer—P1CC · 43
Head And Neck Carcinoma—P1CC · 43
Ovarian Carcinoma—P1CC · 43

Scientific Foundation

Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR

Planned for methodology v0.2.

Development Feasibility

How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR

Planned for methodology v0.2.

Commercial Opportunity

Commercial prize: addressable population, unmet need, and the value case for the indication.
NR

Planned for methodology v0.2.

IP & Exclusivity

Exclusivity position, covering patent protection and freedom-to-operate runway.
NR

Planned for methodology v0.2.

Manufacturing & Supply

Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR

Planned for methodology v0.2.

Related assets

Citation

Floatz Terminal. Immunoglobulin G1 [De-236-Glycine,267-Glutamic Acid,De-C-Terminal Lysine], Anti-(Human Tumor Necrosis Factor Receptor Tnfrsf9) (Human-Mus Musculus Monoclonal Lvgn6051 ?1-Chain), Disulfide With Human-Mus Musculus Monoclonal Lvgn6051 ?-Chain, Dimer in Hepatocellular Carcinoma. Methodology v0.2.
Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026.
Accessed July 14, 2026.
https://terminal.floatz.ai/assets/immunoglobulin-g1-de-236-glycine267-glutamic-acidde-c-terminal-lysine-anti-human-tumor-necrosis-factor-receptor-tnfrsf9-human-mus-musculus-monoclonal-lvgn6051-1-chain-disulfide-with-human-mus-musculus-monoclonal-lvgn6051-chain-dimer-hepatocellular-carcinoma

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →